Quanterix announces commercialization of p-Tau 217 test kit

Quanterix (QTRX) “announced it is making its Simoa(R) p-Tau 217 Planar Kit commercially available as part of the next phase of Alzheimer’s Disease test development. The kit uses p-Tau 217 antibody technology licensed from Eli Lilly and Company (LLY) and Quanterix’s SP-X platform. In March 2022, Quanterix first announced its entry into license and collaboration agreements with Lilly, which specified the initial development of a test for the Eli Lilly Clinical Diagnostics Laboratory, a wholly owned subsidiary of Lilly. Now, with the Simoa(R) p-Tau 217 Planar Kit, Quanterix will expand access to this technology by selling customers research use only (RUO) instrumentation and consumables to develop p-Tau 217 blood tests and services using p-Tau 217 antibody technology licensed from Lilly. The Simoa(R) p-Tau 217 Planar Kit will be available immediately.”